Cargando…

Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study

BACKGROUND: Tumor microenvironment (TME) is a dynamic setting and changes in TILs and their subpopulations are potential candidates to influence the metastatic process. Aim of this pilot study is to describe the changes occurring between primary breast cancers and their paired metastases in terms of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeppellini, Annalisa, Galimberti, Stefania, Leone, Biagio Eugenio, Pacifico, Claudia, Riva, Francesca, Cicchiello, Federica, Capici, Serena, Maggioni, Claudia, Sala, Luca, Cazzaniga, Marina Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944604/ https://www.ncbi.nlm.nih.gov/pubmed/33691674 http://dx.doi.org/10.1186/s12885-021-07960-z

Ejemplares similares

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
por: Cogliati, Viola, et al.
Publicado: (2022)

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
por: Pepe, F. F., et al.
Publicado: (2022)

The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data
por: Capici, Serena, et al.
Publicado: (2021)

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
por: Cazzaniga, Marina Elena, et al.
Publicado: (2022)

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study
por: Cazzaniga, M. E., et al.
Publicado: (2014)

Suicidality and Illness Course Worsening in a Male Patient with Bipolar Disorder during Tamoxifen Treatment for ER+/HER2+ Breast Cancer
por: Carmassi, Claudia, et al.
Publicado: (2021)

Financing the cultural and creative industries through crowdfunding: the role of national cultural dimensions and policies
por: Cicchiello, Antonella Francesca, et al.
Publicado: (2022)

Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything
por: Capici, Serena, et al.
Publicado: (2022)

Targeting the ERβ/HER Oncogenic Network in KRAS Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy
por: Almotlak, Abdulaziz A., et al.
Publicado: (2021)

Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic
por: Russo, Selena, et al.
Publicado: (2022)

Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study
por: Terraneo, Marco, et al.
Publicado: (2022)

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study
por: Cazzaniga, M. E., et al.
Publicado: (2016)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Transmissible ER stress shapes the leukemic microenvironment
por: Butler, John T., et al.
Publicado: (2019)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
por: Collins, Denis, et al.
Publicado: (2017)

Ouabain and Digoxin Activate the Proteasome and the Degradation of the ERα in Cells Modeling Primary and Metastatic Breast Cancer
por: Busonero, Claudia, et al.
Publicado: (2020)

Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer Patients
por: Mazo, Claudia, et al.
Publicado: (2020)

A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells
por: Cipolletti, Manuela, et al.
Publicado: (2021)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Expression of ERβ, ERα and Her-2 and distribution of molecular subtypes in Uygur and Han patients with breast cancer
por: GUO, LIYING, et al.
Publicado: (2014)

Dynamin II is required for 17β-estradiol signaling and autophagy-based ERα degradation
por: Totta, Pierangela, et al.
Publicado: (2016)

MRI-Based Radiomics Approach Predicts Tumor Recurrence in ER + /HER2 − Early Breast Cancer Patients
por: Chiacchiaretta, Piero, et al.
Publicado: (2023)

Radioimmunotheranostic Pair Based on the Anti-HER2 Monoclonal Antibody: Influence of Chelating Agents and Radionuclides on Biological Properties
por: Miranda, Ana Cláudia Camargo, et al.
Publicado: (2021)

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer
por: Bahnassy, Shaymaa, et al.
Publicado: (2023)

Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status
por: Valentini, Anna Maria, et al.
Publicado: (2019)

β2-microglobulin has a different regulatory molecular mechanism between ER(+) and ER(−) breast cancer with HER2(−)
por: Chai, Dandan, et al.
Publicado: (2019)

Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes
por: Watson, Spencer S., et al.
Publicado: (2018)

Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade
por: Batalha, Sofia, et al.
Publicado: (2023)

Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival
por: Tumedei, Maria Maddalena, et al.
Publicado: (2023)

Do body composition parameters correlate with response to targeted therapy in ER+/HER2- metastatic breast cancer patients? Role of sarcopenia and obesity
por: Kripa, Endi, et al.
Publicado: (2022)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)

Modulation of Acid Sphingomyelinase in Melanoma Reprogrammes the Tumour Immune Microenvironment
por: Assi, Emma, et al.
Publicado: (2015)

EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer
por: Ye, Peng, et al.
Publicado: (2022)

NGAL as a Potential Target in Tumor Microenvironment
por: Crescenzi, Elvira, et al.
Publicado: (2021)

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
por: Roßwag, Sven, et al.
Publicado: (2021)

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
por: Triulzi, Tiziana, et al.
Publicado: (2018)

Endogenous and Therapeutic Estrogens: Maestro Conductors of the Microenvironment of ER+ Breast Cancers
por: Schuler, Linda A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8mgc0kp646tvbo8jrgneut4r3r